Form 4: Solenos Therapeutics Grants Equity to Senior VP

Solenos Therapeutics' Sr. VP of Clinical Development, Michael F. Huang, received grants of restricted stock units and employee stock options.

Summary

• Michael F. Huang, Senior VP of Clinical Development at SOLENO THERAPEUTICS INC (SLNO), was granted 10,400 restricted stock units (RSUs) on January 21, 2026.
• Each RSU represents a contingent right to receive one share of Common Stock, with 100% vesting on December 15, 2027, contingent on continued service.
• Huang also acquired 11,900 employee stock options (right to buy) with an exercise price of $43.65 on January 21, 2026.
• These options will vest at a rate of 1/48th of the shares on February 1, 2026, and each one-month anniversary thereafter, subject to continued service, and expire on January 21, 2036.
• Following these transactions, Huang beneficially owns 46,405 shares of Common Stock (including RSUs) and 11,900 employee stock options.

Sentiment

Score: 7

Explanation: The grant of equity awards to a senior executive is generally a positive signal as it aligns management's interests with shareholders, indicating continued commitment to the company's long-term success. However, it is a compensation event rather than an open market purchase, so the positive impact is moderate.

Positives

• The grant of equity awards to a senior executive aligns their long-term interests with those of shareholders, incentivizing performance and retention.
• The vesting schedules for both RSUs and stock options encourage continued service and commitment to the company's strategic goals.

Risks

• The vesting of both restricted stock units and employee stock options is contingent upon the reporting person continuing to be a Service Provider, meaning forfeiture if employment ceases before vesting dates.

Future Outlook

The equity grants with multi-year vesting schedules indicate a long-term commitment from the executive to the company's future performance and success, aligning their financial incentives with shareholder value creation over the coming years.

Industry Context

The granting of restricted stock units and employee stock options is a standard practice in the biotechnology and pharmaceutical industries for executive compensation, aiming to attract, retain, and motivate key talent by linking their compensation to the company's stock performance and long-term value creation.

Related Party Transactions

• Grant of restricted stock units and employee stock options to Michael F. Huang, Senior VP of Clinical Development, as part of his executive compensation package, which is a transaction between the company and a related party (an executive).

Stakeholder Impact

• Shareholders: The equity grants align the executive's financial interests with shareholder value, potentially leading to more focused efforts on long-term growth.
• Employees: Standard executive compensation practices can influence overall compensation philosophy and morale within the company.

Next Steps

• Michael F. Huang must continue to be a Service Provider to Solenos Therapeutics through the specified vesting dates to receive the shares from the RSUs and to exercise the stock options.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a senior executive, which is a standard compensation practice. While it aligns management's interests with shareholders, it does not provide new fundamental information about the company's operational performance or strategic direction to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

SOLENO THERAPEUTICS, SLNO, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Grant, Executive Compensation, Vesting